» Articles » PMID: 23645752

Regulation of Target Genes of PAX3-FOXO1 in Alveolar Rhabdomyosarcoma

Overview
Journal Anticancer Res
Specialty Oncology
Date 2013 May 7
PMID 23645752
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

Background: The majority of alveolar rhabdomyosarcoma (ARMS) are distinguished through the paired box 3-forkhead box protein O1 (PAX3-FOXO1) fusion oncoprotein, being generated by a 2;13 chromosomal translocation. This fusion-positive ARMS is the most clinically difficult type of rhabdomyosarcoma. The present study characterized four genes [gremlin 1 (GREM1), death-associated protein kinase-1 (DAPK1), myogenic differentiation-1 (MYOD1), and hairy/enhancer-of-split related with YRPW motif-1 (HEY1)] as targets of PAX3-FOXO1.

Materials And Methods: The expression of the four genes, PAX3-FOXO1, and v-myc myelocytomatosis viral-related oncogene, neuroblastoma-derived (avian) (MYCN) was determined in various ARMS cell models and primary tumors. The roles of PAX3-FOXO1 and MYCN expression were examined.

Results: Pulse-chase and cycloheximide experiments suggest that GREM1, DAPK1, and MYOD1 are directly regulated by PAX3-FOXO1. PAX3-FOXO1 appears to indirectly down-regulate HEY1 by up-regulating MYCN. Data reveal that the growth-suppressive activity of high PAX3-FOXO1 expression is closely-associated with up-regulation of the GREM1 and DAPK1 tumor-suppressor genes.

Conclusion: This study characterized four downstream targets of PAX3-FOXO1 that contribute to the biological activities of growth suppression and myogenic differentiation.

Citing Articles

Untangling the Role of MYC in Sarcomas and Its Potential as a Promising Therapeutic Target.

Sias F, Zoroddu S, Migheli R, Bagella L Int J Mol Sci. 2025; 26(5).

PMID: 40076599 PMC: 11900228. DOI: 10.3390/ijms26051973.


Hyperactivation of oncogenic driver pathways as a precision therapeutic strategy.

Wood K Nat Genet. 2023; 55(10):1613-1614.

PMID: 37749245 DOI: 10.1038/s41588-023-01493-w.


Interleukin-24 (IL24) Is Suppressed by PAX3-FOXO1 and Is a Novel Therapy for Rhabdomyosarcoma.

Lacey A, Hedrick E, Cheng Y, Mohankumar K, Warren M, Safe S Mol Cancer Ther. 2018; 17(12):2756-2766.

PMID: 30190424 PMC: 6279487. DOI: 10.1158/1535-7163.MCT-18-0118.


The Emerging Roles of Forkhead Box (FOX) Proteins in Osteosarcoma.

Zhang W, Duan N, Song T, Li Z, Zhang C, Chen X J Cancer. 2017; 8(9):1619-1628.

PMID: 28775781 PMC: 5535717. DOI: 10.7150/jca.18778.